digitoxin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
881 71-63-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • digitoxin
  • digitoxoside
  • cardidigin
  • cardigin
  • carditoxin
  • coramedan
  • cristapurat
  • crystodigin
  • digicor
  • digipural
  • digisidin
  • digitophyllin
  • digitoxigenin tridigitoxoside
  • myodigin
  • purpurid
  • tradigal
  • unidigin
A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
  • Molecular weight: 764.95
  • Formula: C41H64O13
  • CLOGP: 2.85
  • LIPINSKI: 2
  • HAC: 13
  • HDO: 5
  • TPSA: 182.83
  • ALOGS: -4.42
  • ROTB: 7

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 mg O
0.10 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 30 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.44 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.04 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.07 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 180 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
None FDA LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 220.44 30.18 146 4009 201256 63283611
Atrial fibrillation 216.99 30.18 119 4036 116517 63368350
Product prescribing error 162.40 30.18 62 4093 26227 63458640
Arrhythmia 153.13 30.18 66 4089 38074 63446793
Product monitoring error 151.89 30.18 39 4116 4477 63480390
Bradycardia 136.68 30.18 75 4080 73152 63411715
Fall 124.73 30.18 140 4015 392194 63092673
Tachycardia 103.68 30.18 75 4080 118081 63366786
Anaemia 95.21 30.18 106 4049 293324 63191543
Therapeutic drug monitoring analysis not performed 88.55 30.18 20 4135 1332 63483535
Haematochezia 84.01 30.18 49 4106 53495 63431372
Syncope 77.62 30.18 63 4092 117322 63367545
Systemic infection 68.23 30.18 21 4134 4639 63480228
Dyspnoea 62.89 30.18 135 4020 661178 62823689
Toxic epidermal necrolysis 58.62 30.18 30 4125 25304 63459563
Cardiac failure 57.10 30.18 47 4108 89095 63395772
Dizziness 55.58 30.18 100 4055 429825 63055042
Drug ineffective 50.79 30.18 5 4150 1044760 62440107
Stevens-Johnson syndrome 50.46 30.18 27 4128 24923 63459944
Cerebrospinal fluid retention 49.55 30.18 8 4147 84 63484783
Fracture 44.75 30.18 23 4132 19561 63465306
Cerebral ventricular rupture 42.73 30.18 8 4147 208 63484659
Labelled drug-drug interaction medication error 40.36 30.18 19 4136 13380 63471487
Spontaneous haemorrhage 39.98 30.18 9 4146 590 63484277
Gastric pH increased 39.09 30.18 6 4149 44 63484823
Therapeutic drug monitoring analysis incorrectly performed 39.02 30.18 8 4147 336 63484531
Cerebellar infarction 37.79 30.18 11 4144 2008 63482859
Dehydration 37.19 30.18 51 4104 173303 63311564
Pulmonary vein occlusion 34.31 30.18 6 4149 105 63484762
Reflexes abnormal 33.57 30.18 8 4147 673 63484194
Atrial flutter 32.99 30.18 15 4140 9757 63475110
Wound 31.99 30.18 46 4109 163217 63321650
Diverticulum intestinal haemorrhagic 31.42 30.18 9 4146 1552 63483315
Restlessness 31.13 30.18 21 4134 29432 63455435
Lip erosion 30.58 30.18 8 4147 985 63483882
Pallor 30.42 30.18 21 4134 30547 63454320

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 215.96 33.74 164 4828 128105 34823834
Rectal prolapse 104.54 33.74 22 4970 470 34951469
Renal cyst haemorrhage 104.33 33.74 23 4969 616 34951323
Product prescribing error 100.89 33.74 54 4938 22873 34929066
Product monitoring error 98.59 33.74 33 4959 4348 34947591
Haematochezia 92.52 33.74 66 4926 46468 34905471
Intraductal papillary mucinous neoplasm 91.47 33.74 20 4972 515 34951424
Oedema peripheral 83.85 33.74 94 4898 119718 34832221
SARS-CoV-2 antibody test positive 78.93 33.74 17 4975 407 34951532
Vena cava injury 76.84 33.74 16 4976 324 34951615
Abdominal wall haemorrhage 76.48 33.74 17 4975 473 34951466
Atrial fibrillation 75.51 33.74 90 4902 122303 34829636
Carotid arteriosclerosis 75.51 33.74 22 4970 1836 34950103
Delayed graft function 71.63 33.74 22 4970 2199 34949740
Dyspnoea 69.32 33.74 160 4832 376622 34575317
Vascular anastomotic haemorrhage 67.73 33.74 14 4978 273 34951666
Bradycardia 66.56 33.74 67 4925 75351 34876588
Mean cell volume increased 63.95 33.74 22 4970 3147 34948792
Systemic infection 63.66 33.74 25 4967 5187 34946752
Spinal stenosis 63.39 33.74 25 4967 5244 34946695
Aortic dilatation 63.22 33.74 18 4974 1383 34950556
Perineal cyst 62.63 33.74 13 4979 259 34951680
Diverticulum intestinal 62.50 33.74 23 4969 3998 34947941
Hyperparathyroidism secondary 61.22 33.74 18 4974 1550 34950389
Aortic arteriosclerosis 59.31 33.74 23 4969 4613 34947326
Renal artery stenosis 58.78 33.74 19 4973 2242 34949697
Vascular compression 58.43 33.74 13 4979 363 34951576
Hepatosplenomegaly 58.05 33.74 22 4970 4147 34947792
Spinal osteoarthritis 57.46 33.74 26 4966 7657 34944282
Actinic keratosis 56.10 33.74 22 4970 4545 34947394
Intervertebral disc space narrowing 49.62 33.74 14 4978 1041 34950898
Labelled drug-drug interaction medication error 46.29 33.74 28 4964 14911 34937028
Blood 25-hydroxycholecalciferol decreased 45.67 33.74 10 4982 259 34951680
Swelling of eyelid 44.45 33.74 13 4979 1098 34950841
Left ventricular hypertrophy 43.92 33.74 22 4970 8108 34943831
Restless legs syndrome 43.36 33.74 22 4970 8332 34943607
Therapeutic drug monitoring analysis not performed 43.16 33.74 11 4981 554 34951385
Activated partial thromboplastin time prolonged 42.53 33.74 22 4970 8673 34943266
Electrocardiogram abnormal 41.25 33.74 22 4970 9225 34942714
Vitamin D decreased 40.09 33.74 16 4976 3460 34948479
Glycosylated haemoglobin increased 39.66 33.74 23 4969 11337 34940602
Therapeutic drug monitoring analysis incorrectly performed 38.38 33.74 9 4983 319 34951620
Squamous cell carcinoma of skin 37.90 33.74 22 4970 10859 34941080
Benign prostatic hyperplasia 36.93 33.74 24 4968 14471 34937468
C-reactive protein increased 35.27 33.74 41 4951 54057 34897882
Vertigo 34.84 33.74 29 4963 25507 34926432
Wound 33.97 33.74 23 4969 14841 34937098

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 413.65 30.31 295 8389 274943 79460761
Atrial fibrillation 262.27 30.31 197 8487 197689 79538015
Product prescribing error 257.13 30.31 116 8568 44697 79691007
Product monitoring error 239.39 30.31 72 8612 8834 79726870
Bradycardia 190.61 30.31 140 8544 135417 79600287
Haematochezia 171.49 30.31 111 8573 87534 79648170
Systemic infection 128.53 30.31 46 8638 9706 79725998
Arrhythmia 125.71 30.31 80 8604 61192 79674512
Dyspnoea 125.25 30.31 282 8402 856743 78878961
Therapeutic drug monitoring analysis not performed 123.98 30.31 31 8653 1905 79733799
Anaemia 112.37 30.31 185 8499 444830 79290874
Renal cyst haemorrhage 108.69 30.31 23 8661 669 79735035
Intraductal papillary mucinous neoplasm 88.88 30.31 20 8664 778 79734926
SARS-CoV-2 antibody test positive 82.92 30.31 17 8667 422 79735282
Labelled drug-drug interaction medication error 82.53 30.31 46 8638 27604 79708100
Oedema peripheral 81.93 30.31 118 8566 252170 79483534
Vena cava injury 80.60 30.31 16 8668 336 79735368
Fall 79.37 30.31 168 8516 487461 79248243
Toxic epidermal necrolysis 78.68 30.31 53 8631 44528 79691176
Rectal prolapse 77.92 30.31 22 8662 2156 79733548
Abdominal wall haemorrhage 75.16 30.31 17 8667 677 79735027
Therapeutic drug monitoring analysis incorrectly performed 74.63 30.31 17 8667 699 79735005
Carotid arteriosclerosis 73.61 30.31 22 8662 2634 79733070
Syncope 71.94 30.31 93 8591 179356 79556348
Vascular anastomotic haemorrhage 71.51 30.31 14 8670 273 79735431
Aortic dilatation 68.00 30.31 19 8665 1793 79733911
Delayed graft function 67.59 30.31 22 8662 3485 79732219
Spontaneous haemorrhage 67.18 30.31 16 8668 801 79734903
Perineal cyst 66.28 30.31 13 8671 256 79735448
Cardiac failure 61.65 30.31 80 8604 154762 79580942
Drug ineffective 57.68 30.31 23 8661 1080890 78654814
Wound 57.51 30.31 67 8617 116112 79619592
Hyperparathyroidism secondary 56.64 30.31 18 8666 2642 79733062
Vascular compression 56.46 30.31 13 8671 561 79735143
Tachycardia 55.96 30.31 82 8602 177686 79558018
Actinic keratosis 55.90 30.31 22 8662 6020 79729684
Hepatosplenomegaly 55.80 30.31 22 8662 6047 79729657
Renal artery stenosis 55.77 30.31 19 8665 3463 79732241
Mean cell volume increased 55.16 30.31 22 8662 6231 79729473
Dizziness 55.05 30.31 153 8531 526288 79209416
Restlessness 54.13 30.31 43 8641 46449 79689255
Aortic arteriosclerosis 53.98 30.31 24 8660 8894 79726810
Stevens-Johnson syndrome 53.88 30.31 40 8644 39126 79696578
Diverticulum intestinal 51.58 30.31 23 8661 8582 79727122
Electrocardiogram abnormal 50.36 30.31 28 8656 16709 79718995
Activated partial thromboplastin time prolonged 48.91 30.31 26 8658 14202 79721502
Pallor 47.25 30.31 41 8643 50021 79685683
Intervertebral disc space narrowing 46.48 30.31 14 8670 1721 79733983
Benign prostatic hyperplasia 45.01 30.31 23 8661 11589 79724115
Blood 25-hydroxycholecalciferol decreased 44.69 30.31 10 8674 379 79735325
Spinal osteoarthritis 44.69 30.31 26 8658 16901 79718803
Cerebrospinal fluid retention 44.50 30.31 8 8676 96 79735608
Spinal stenosis 43.67 30.31 25 8659 15766 79719938
Left ventricular hypertrophy 42.90 30.31 22 8662 11169 79724535
Squamous cell carcinoma of skin 38.23 30.31 22 8662 14011 79721693
Dehydration 36.21 30.31 82 8602 248105 79487599
Gastric pH increased 35.15 30.31 6 8678 52 79735652
Off label use 34.53 30.31 29 8655 907186 78828518
Renal impairment 33.58 30.31 61 8623 157722 79577982
Restless legs syndrome 33.32 30.31 23 8661 20069 79715635
Personality change 33.31 30.31 18 8666 10152 79725552
Cerebral ventricular rupture 32.64 30.31 8 8676 452 79735252
Thoracic haemorrhage 32.58 30.31 7 8677 219 79735485
Malaise 32.25 30.31 7 8677 489862 79245842
Swelling of eyelid 32.20 30.31 13 8671 3798 79731906
Glycosylated haemoglobin increased 31.83 30.31 22 8662 19238 79716466
Fracture 31.63 30.31 23 8661 21778 79713926

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01AA04 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC GLYCOSIDES
Digitalis glycosides
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:63510 sodium-potassium adenosine triphosphatase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

None




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium/potassium-transporting ATPase subunit alpha-1 Transporter INHIBITOR WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.86 WOMBAT-PK
Signal transducer and activator of transcription 3 Transcription factor IC50 6.15 CHEMBL
Sodium/potassium-transporting ATPase Transporter IC50 8.10 CHEMBL
Sodium/potassium-transporting ATPase subunit alpha-2 Ion channel IC50 6.65 DRUG MATRIX
Sodium/potassium-transporting ATPase subunit alpha-1 Transporter IC50 8.10 CHEMBL

External reference:

IDSource
4017429 VUID
N0000145817 NUI
D00297 KEGG_DRUG
216288 RXNORM
4017429 VANDF
C0012258 UMLSCUI
CHEBI:28544 CHEBI
F9R PDB_CHEM_ID
CHEMBL254219 ChEMBL_ID
D004074 MESH_DESCRIPTOR_UI
DB01396 DRUGBANK_ID
6782 IUPHAR_LIGAND_ID
1547 INN_ID
E90NZP2L9U UNII
441207 PUBCHEM_CID
195 MMSL
4596 MMSL
d00209 MMSL
000592 NDDF
373534001 SNOMEDCT_US
81728006 SNOMEDCT_US

Pharmaceutical products:

None